Nemaura Medical (NASDAQ:NMRD – Get Free Report) and Beauty Health (NASDAQ:SKIN – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk and dividends.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for Nemaura Medical and Beauty Health, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nemaura Medical | 0 | 0 | 0 | 0 | 0.00 |
| Beauty Health | 1 | 3 | 1 | 0 | 2.00 |
Beauty Health has a consensus price target of $2.55, suggesting a potential upside of 61.39%. Given Beauty Health’s stronger consensus rating and higher probable upside, analysts clearly believe Beauty Health is more favorable than Nemaura Medical.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nemaura Medical | $80,000.00 | 0.00 | -$14.14 million | ($0.39) | N/A |
| Beauty Health | $398.00 million | 0.49 | -$100.12 million | ($0.42) | -3.76 |
Nemaura Medical has higher earnings, but lower revenue than Beauty Health. Beauty Health is trading at a lower price-to-earnings ratio than Nemaura Medical, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Nemaura Medical and Beauty Health’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nemaura Medical | N/A | N/A | N/A |
| Beauty Health | -8.11% | -44.83% | -3.54% |
Institutional & Insider Ownership
4.4% of Nemaura Medical shares are held by institutional investors. Comparatively, 93.3% of Beauty Health shares are held by institutional investors. 40.4% of Nemaura Medical shares are held by insiders. Comparatively, 41.0% of Beauty Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Risk and Volatility
Nemaura Medical has a beta of 0.13, suggesting that its stock price is 87% less volatile than the S&P 500. Comparatively, Beauty Health has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500.
Summary
Beauty Health beats Nemaura Medical on 7 of the 12 factors compared between the two stocks.
About Nemaura Medical
Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.
About Beauty Health
The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health. The company was founded in 1997 and is headquartered in Long Beach, California.
Receive News & Ratings for Nemaura Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nemaura Medical and related companies with MarketBeat.com's FREE daily email newsletter.
